NASDAQ:DXCMDexCom Stock Price, Forecast & News

DexCom's stock was trading at $252.42 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, DXCM stock has increased by 68.5% and is now trading at $425.30.
View which stocks have been most impacted by COVID-19.

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 5 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for DexCom.

DexCom is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for DexCom.

DexCom, Inc. (NASDAQ:DXCM) issued its quarterly earnings data on Tuesday, July, 28th. The medical device company reported $0.79 EPS for the quarter, beating analysts' consensus estimates of $0.31 by $0.48. The medical device company earned $451.80 million during the quarter, compared to the consensus estimate of $415.21 million. DexCom had a net margin of 11.93% and a return on equity of 29.01%. The company's quarterly revenue was up 34.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.08 EPS.
View DexCom's earnings history.

DexCom issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, July, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.85-1.85 billion, compared to the consensus revenue estimate of $1.8 billion.

21 brokers have issued 1 year target prices for DexCom's stock. Their forecasts range from $190.00 to $500.00. On average, they anticipate DexCom's share price to reach $393.20 in the next year. This suggests that the stock has a possible downside of 7.5%.
View analysts' price targets for DexCom.

Headlines about DXCM stock have been trending extremely negative on Friday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. DexCom earned a media sentiment score of -4.0 on InfoTrie's scale. They also gave news coverage about the medical device company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.
View the latest news about DexCom.

Some companies that are related to DexCom include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Stryker (SYK), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR), Steris (STE) and ABIOMED (ABMD).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), Alibaba Group (BABA), Paypal (PYPL), salesforce.com (CRM), Netflix (NFLX), Trade Desk (TTD), Advanced Micro Devices (AMD), Shopify (SHOP), Square (SQ) and ServiceNow (NOW).

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

DexCom's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.73%), Mint Tower Capital Management B.V. (8.20%), Jennison Associates LLC (2.88%), Blair William & Co. IL (1.12%), Federated Hermes Inc. (0.61%) and Gilder Gagnon Howe & Co. LLC (0.53%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman and Steven Robert Pacelli.
View institutional ownership trends for DexCom.

DXCM stock was sold by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank, Holocene Advisors LP, Columbus Circle Investors, Ardevora Asset Management LLP, Frontier Capital Management Co. LLC, Sumitomo Mitsui Trust Holdings Inc., Macquarie Group Ltd., and Gilder Gagnon Howe & Co. LLC. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Barbara Kahn, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman, and Steven Robert Pacelli.
View insider buying and selling activity for DexCom.

DXCM stock was bought by a variety of institutional investors in the last quarter, including Mint Tower Capital Management B.V., Vanguard Group Inc., Coatue Management LLC, Principal Financial Group Inc., New York State Teachers Retirement System, Jackson Square Partners LLC, Bessemer Group Inc., and Jennison Associates LLC.
View insider buying and selling activity for DexCom.

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DXCM stock can currently be purchased for approximately $425.30.

DexCom has a market capitalization of $40.72 billion and generates $1.48 billion in revenue each year. The medical device company earns $101.10 million in net income (profit) each year or $1.84 on an earnings per share basis. DexCom employs 3,900 workers across the globe.

The official website for DexCom is www.dexcom.com.

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]